Kari C Nadeau
Stanford University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kari C Nadeau as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:40 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03181009 · Multi OIT to Test Immune Markers After Minimum Maintenance DoseAndrew Long, PharmD · completed · Food Allergy · principal investigator
- Ph2NCT02103270 · The Peanut Oral Immunotherapy Study: Safety, Efficacy and DiscoveryStanford University · completed · Peanut Allergy · principal investigator
- Ph1NCT01057498 · Safety Study of Nebulized RNS60 to Treat Asthma.Revalesio Corporation · completed · Asthma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 8 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical CoreU19AI167903 · NIAID · STANFORD UNIVERSITY · fiscal years 2022 to 2026 · $242,976 awarded in 2026Same name and institution; not confirmed by an ID
- Clinical CoreP01AI153559 · NIAID · STANFORD UNIVERSITY · fiscal years 2021 to 2025 · $472,641 awarded in 2025Same name and institution; not confirmed by an ID
- Clinical-Virology CoreU54CA260517 · NCI · STANFORD UNIVERSITY · fiscal years 2020 to 2024 · $187,845 awarded in 2024Same name and institution; not confirmed by an ID
- Tracking allergen specific T cells in multi-food allergyU19AI104209 · NIAID · STANFORD UNIVERSITY · fiscal years 2013 to 2023 · $374,941 awarded in 2023Same name and institution; not confirmed by an ID
- Interaction between genetic, lifestyle and environmental factors determining circulating angiotensin-converting enzyme 2 protein expression: implications for the severity of COVID-19 infectionR21ES033049 · NIEHS · STANFORD UNIVERSITY · fiscal years 2021 to 2022 · $175,246 awarded in 2022Same name and institution; not confirmed by an ID
- T Cell Reagent Research for Monitoring T Cell in Food AllergyU01AI140498 · NIAID · STANFORD UNIVERSITY · fiscal years 2018 to 2022 · $340,781 awarded in 2022Same name and institution; not confirmed by an ID
- Effects of IgE Blockade on T Cells in Food AllergyR01AI140134 · NIAID · STANFORD UNIVERSITY · fiscal years 2018 to 2021 · $392,500 awarded in 2021Same name and institution; not confirmed by an ID
- Extension of clinical data structured into the ImmPort model and cross-study data exploration and visualization user interfaceUH2AI145837 · NIAID · STANFORD UNIVERSITY · fiscal years 2019 · $234,750 awarded in 2019Same name and institution; not confirmed by an ID
- Secondhand smoke and asthma: Mechanistic outcomes of DNA methylation in T cellsR01HL118612 · NHLBI · STANFORD UNIVERSITY · fiscal years 2014 to 2017 · $529,389 awarded in 2017Same name and institution; not confirmed by an ID
- Phenotyping/Epigenetic studies of PAH-associated Treg impairment in asthmaR01ES020926 · NIEHS · STANFORD UNIVERSITY · fiscal years 2012 to 2016 · $284,860 awarded in 2016Same name and institution; not confirmed by an ID
- Effects of Tobacco Exposure on Immune ResponsesR21ES022153 · NIEHS · STANFORD UNIVERSITY · fiscal years 2013 to 2014 · $246,674 awarded in 2014Same name and institution; not confirmed by an ID
- Development of Improved Diagnostic Allergy TestR21AI095838 · NIAID · STANFORD UNIVERSITY · fiscal years 2011 to 2012 · $237,000 awarded in 2012Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:40 UTC. The ranking covers the 200 most relevant of 42 PubMed records, and a shared surname and initials can bring in a namesake. All 42 on PubMed
- Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3).J Allergy Clin Immunol · 2014394 citationsRCR 11.8
- 292 citationsRCR 26.0
- 283 citationsRCR 13.3
- Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy.J Allergy Clin Immunol · 2011279 citationsRCR 8.6
- Omalizumab facilitates rapid oral desensitization for peanut allergy.J Allergy Clin Immunol · 2017259 citationsRCR 10.9
- Twin and family studies reveal strong environmental and weaker genetic cues explaining heritability of eosinophilic esophagitis.J Allergy Clin Immunol · 2014223 citationsRCR 7.6
- Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial.Lancet Gastroenterol Hepatol · 2018206 citationsRCR 9.8
- 174 citationsRCR 7.5
- 168 citationsRCR 7.5
- Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy.J Allergy Clin Immunol · 2012125 citationsRCR 4.4